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Abstract
Autoreactive CD8 T cells play a central role in the destruction of pancreatic islet Ś-cells that leads 
to type 1 diabetes, yet the key features of this immune-mediated process remain poorly defined. In 
this study, we combined high definition polychromatic flow cytometry with ultrasensitive peptide-
human leukocyte antigen class I (pHLAI) tetramer staining to quantify and characterize Ś-cell-
specific CD8 T cell populations in patients with recent onset type 1 diabetes and healthy controls. 
Remarkably, we found that Ś-cell-specific CD8 T cell frequencies in peripheral blood were similar 
between subject groups. In contrast to healthy controls, however, patients with newly diagnosed 
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type 1 diabetes displayed hallmarks of antigen-driven expansion uniquely within the Ś-cell-
specific CD8 T cell compartment. Molecular analysis of selected Ś-cell-specific CD8 T cell 
populations further revealed highly skewed oligoclonal T cell receptor (TCR) repertoires 
comprising exclusively private clonotypes. Collectively, these data identify novel and distinctive 
features of disease-relevant CD8 T cells that inform the immunopathogenesis of type 1 diabetes.
Type 1 diabetes is an autoimmune disease characterized by T cell-mediated destruction of 
insulin-producing Ś-cells in the islets of Langerhans (1; 2). Several lines of evidence 
implicate the CD8 T cell lineage in this process: (i) CD8 T cells predominate in islet-centred 
leukocytic infiltrates close to diagnosis (3; 4); (ii) autoreactive CD8 T cells with Ś-cell 
epitope specificities have been detected in such early infiltrates (3); (iii) CD8 T cell clones 
specific for preproinsulin-derived peptides can kill Ś-cells in vitro (5; 6); and (iv) large 
genetic association studies link disease susceptibility to the inheritance of specific human 
leukocyte antigen class I (HLAI) alleles (7). This mounting functional and epidemiological 
evidence, combined with the expanding array of reported HLAI-restricted Ś-cell epitopes (8; 
9), provides a strong rationale for detailed studies of autoreactive CD8 T cells in type 1 
diabetes.
Technological advances have facilitated the design of CD8-centric studies, enabling 
enhanced data retrieval from cell-limited samples to illuminate fundamental 
immunobiological processes. In particular, antigen-specific CD8 T cells can now be 
enumerated routinely by flow cytometry irrespective of functional outputs due to the advent 
of recombinant peptide-HLAI (pHLAI) proteins in various fluorochrome-tagged multimeric 
formats (10-13). Moreover, developments in instrumentation and fluorochrome technology 
continue to expand the horizons of polychromatic flow cytometry (14; 15), facilitating the 
identification of functionally distinct T cell subsets across a spectrum of phenotypic 
heterogenity (16). The collective application of such innovations has transformed our 
understanding of T cell ontogeny in response to infectious “ foreign”  antigens. However, it is 
unclear whether the emerging conceptual frameworks extend similarly to autoimmune 
processes.
Although Ś-cell epitope-specific CD8 T cell expansions have been identified in the 
peripheral blood of patients with type 1 diabetes (6; 17), the functional and phenotypic 
properties of these cells in the context of disease relevance remain largely uncharacterized. 
This is a significant knowledge gap for two important reasons. First, it cannot be assumed 
that autoreactive CD8 T cells will follow the rules of antigen engagement established in 
previous studies. Indeed, autoreactive T cell receptors (TCRs) characteristically display low 
affinity interactions with their cognate pHLA antigens (18; 19), presumably reflecting the 
effects of thymic culling to eliminate potentially dangerous self-specific clonotypes from the 
peripheral repertoire. Moreover, autoantigens are expressed continuously and guarded by 
peripheral tolerance mechanisms designed to limit cognate T cell expansion (1). Second, 
immune intervention strategies designed specifically to target either effector T cells or 
innate inflammatory pathways that could impact adaptive immune responses are currently 
being trialed in type 1 diabetes (20-23). The identification of T cell-related biomarkers could 
facilitate immune monitoring in this setting and delineate correlates of therapeutic efficacy. 
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Accordingly, we undertook a multiparametric analysis of Ś-cell-specific CD8 T cell 
populations in patients with type 1 diabetes and healthy controls to identify the key cellular 
features associated with disease.
RESEARCH DESIGN AND METHODS
Study subjects
The study cohort comprised 14 HLA-A*0201+ patients (mean age, 30 years +/− SD = 6.4) 
with newly diagnosed type 1 diabetes (mean disease duration, 4 months) and 14 HLA-
A*0201+ healthy controls (mean age, 30 years +/− SD = 5.0). Autoantibodies against 
GAD65 and IA-2 were detected in 64% (9/14) and 71% (10/14) of patients in the type 1 
diabetes group, respectively. Local research ethics committee approval (National Research 
Ethics Committee, Bromley NRES Committee, Ref 08/H0805/14) was granted at each 
participating center and written informed consent was obtained in all cases.
Blood samples
Fresh venous blood was collected into heparinized tubes and transported for processing 
within 3 h of collection. Peripheral blood mononuclear cells (PBMCs) were isolated by 
density gradient centrifugation (Nycomed), washed twice in RPMI-1640 supplemented with 
1% penicillin/streptomycin and 2% human AB serum (all Life Technologies), then 
resuspended in freezing medium comprising 90% heat-inactivated, filter-sterilized fetal 
bovine serum and 10% dimethyl sulfoxide (Sigma-Aldrich). Aliquots of 10-20 × 106 
cells/mL per vial were cooled overnight at a controlled rate of −1°C/min to −80°C prior to 
storage in liquid nitrogen. All samples were analyzed within two years of cryopreservation.
Tetrameric pHLAI complexes
Soluble, fluorochrome-conjugated pHLA-A*0201 tetramers were produced as described 
previously (24). Incorporated peptides were synthesized at >95% purity (BioSynthesis). The 
corresponding epitopes are summarized in Table 1.
Polychromatic flow cytometry
Thawed PBMCs were pre-treated with 50 nM dasatinib before tetramer staining to enhance 
the detection of low avidity T cells as described previously (25). The following monoclonal 
antibodies (mAbs) were used for phenotypic analysis: (i) řCD3-H7APC, řCD4-V500, 
řCD45RO-PECy7, řCD57-FITC, řCD95-PE and řCCR7-PerCPCy5.5 (BD Biosciences); 
(ii) řCD8-QD705 (Life Technologies); and (iii) řCD27-PECy5 (Beckman Coulter). Dead 
cells were excluded from the analysis using the amine-reactive dye ViViD (Life 
Technologies); monocytes and B cells were eliminated in the same dump channel after 
staining with řCD14-PacBlue and řCD19-PacBlue, respectively (Life Technologies). 
Stained samples were acquired using an LSRFortessa™ flow cytometer (BD Biosciences) 
and analyzed with FlowJo version 9.4 (TreeStar Inc.). The gating strategy is illustrated in 
Supplementary Figure 1. For quality control purposes, tetramers were batch-tested prior to 
experimentation using specific CD8 T cell clones where available (5). Assay variability was 
monitored throughout the study using aliquots of cryopreserved PBMCs drawn from a single 
healthy donor at a single time point (Supplementary Figure 2).
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T cell receptor clonotyping
Clonotypic analysis of antigen-specific CD8 T cell populations was performed as described 
previously with minor modifications (26). Briefly, 222-1,071 viable tetramer-labeled 
CD3+CD8+ T cells were sorted directly ex vivo into 1.5 mL microtubes (Sarstedt) containing 
100 µL RNAlater (Applied Biosystems) using a custom-modified FACSAria™ II flow 
cytometer (BD Biosciences). Unbiased amplification of all expressed TRB gene products 
was conducted using a template-switch anchored reverse transcription-polymerase chain 
reaction (RT-PCR) with a 3′ constant region primer (5′-
TGGCTCAAACAAGGAGACCT-3′). Amplicons were sub-cloned, sampled, sequenced and 
analyzed as described previously (24). The IMGT nomenclature is used in this report (27).
Statistical analysis
Single experimental variables were analyzed using the Mann-Whitney U-test or the 
Wilcoxon signed-rank test in GraphPad Prism 5 (GraphPad Software). Multivariate analyses 
of flow cytometric data were performed using the probability binning algorithm in FlowJo 
version 9.7.2 (TreeStar Inc.).
RESULTS
Ex vivo identification of β-cell-specific CD8 T cells
To ensure the optimal detection of autoreactive Ś-cell-specific CD8 T cell populations 
directly ex vivo, we conducted extensive pilot experiments with dasatinib, a reversible 
protein kinase inhibitor (PKI) that lowers the TCR affinity threshold required for tetramer 
binding at the cell surface (25). This approach enables the visualization of low avidity CD8 
T cells that would otherwise remain undetectable and enhances the intensity of tetramer 
staining via active inhibition of TCR downregulation. In line with our previous findings, we 
observed greater frequencies of Ś-cell-specific CD8 T cells in all test subjects after sample 
pre-treatment with dasatinib (Figure 1 A-E) and clearer separation of tetramer-labeled events 
across all specificities (Figure 1 A-G).
Next, we used this approach to compare Ś-cell-specific CD8 T cell frequencies in newly 
diagnosed type 1 diabetes patients and healthy non-diabetic controls across five distinct 
HLA-A*0201-restricted specificities (PPI15-24, InsB10-18, IGRP265-273, IA-2797-805 and 
GAD114-123). Two pHLA-A*0201 tetramers representing immunodominant epitopes from 
common persistent herpesviruses (CMV pp65495-503 and EBV BMLF1280-288) were also 
included for control purposes (Table 1). Again, increased Ś-cell-specific CD8 T cell 
frequencies were observed for the majority of subjects in the presence of dasatinib, reaching 
statistical significance for most specificities in each subject group (Figure 2). Although less 
striking, we noted a similar frequency enhancement for CMV pp65495-503 tetramer-binding 
CD8 T cells. However, this most likely reflects improved visualization of non-amplified 
precursors close to the technical limit of detection rather than a biologically relevant 
phenomenon within the antigen-experienced pool. Consistent with this interpretation, no 
such differences were observed for EBV BMLF1280-288 tetramer-binding CD8 T cells, 
which are driven to expand in the majority of HLA-A*0201+ donors as a consequence of 
high viral prevalence. More importantly, there were no significant differences between type 
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1 diabetes patients and healthy controls with respect to CD8 T cell frequencies across any of 
the seven incorporated specificities, either in the presence or absence of dasatinib. 
Accordingly, we hypothesized that disease-related differences in autoreactive CD8 T cell 
populations may reflect an antigen-driven inflammatory process that does not manifest in 
simple numerical terms, at least within the peripheral circulation.
β-cell-specific CD8 T cells are more differentiated in type 1 diabetes patients
To examine the phenotypic characteristics of Ś-cell-specific CD8 T cells, we constructed a 
polychromatic flow cytometry panel designed to exclude irrelevant events (ViViD, CD14 
and CD19), assign lineage (CD3, CD4 and CD8) and define differentiation status (CD27, 
CD45RO, CD57, CD95 and CCR7). Across all pooled Ś-cell specificities, we found that the 
percentage of autoreactive CD8 T cells with a naïve phenotype (TN - 
CD27+CD45RO−CD57−CD95−CCR7+) was significantly lower in type 1 diabetes patients 
compared to healthy controls (p<0.0001; Figure 3). This pattern held within individual 
specificities, reaching significance for PPI15-24 (p=0.02), IGRP265-273 (p=0.01) and 
IA-2797-805 (p=0.02). Importantly, no such differences were detected between groups for 
either of the virus-derived specificities. Moreover, total naïve CD8 T cell frequencies were 
similar in type 1 diabetes patients and healthy controls (Supplementary Figure 3). Of note, a 
large proportion of CD8 T cells specific for the CMV pp65495-503 epitope displayed a 
classical naïve phenotype. In contrast, very few CD8 T cells specific for the EBV 
BMLF1280-288 epitope were naïve. These observations substantiate the interpretation above 
that dasatinib-mediated frequency amplification within the CMV specificity reflects 
enhanced precursor detection in seronegative individuals.
Collectively, these data suggest that recent onset type 1 diabetes is characterized by antigen-
driven expansion of Ś-cell-specific CD8 T cells into more differentiated compartments, 
likely facilitated by tissue-specific inflammatory processes. Consistent with this notion, 
greater proportions of CD8 T cells with a stem cell memory phenotype (TSCM - 
CD27+CD45RO−CD95+CCR7+) (28) were present in type 1 diabetes patients compared to 
healthy controls across all pooled Ś-cell specificities (p=0.025), as well as individually 
within the autoreactive populations specific for PPI15-24 (p=0.05) and InsB10-18 (p=0.029). 
Moreover, single marker analyses revealed that Ś-cell-specific CD8 T cells expressed higher 
frequencies of CD57 (p=0.0002) and CD95 (p<0.0001) in type 1 diabetes patients compared 
to healthy controls (Figure 4). These surface proteins demarcate terminal differentiation and 
memory status, respectively (16; 29). Conversely, Ś-cell-specific CD8 T cells less frequently 
expressed CD27 and CCR7 in type 1 diabetes patients compared to healthy controls 
(p=0.0002 and p=0.005, respectively). These markers classically delineate naïve and early 
memory T cells (30; 31). No single marker differences between subject groups were 
observed for either of the virus-derived specificities or CD8 T cells as a whole.
To extend these findings, we used frequency difference gating and probability binning to 
conduct multivariate analyses across concatenated datasets (32; 33). A phenotypically 
distinct CD27intermediateCD95+ population of CD8 T cells was identified in type 1 diabetes 
patients at significantly higher frequencies compared to healthy controls for the PPI15-24 
(p<0.01), IGRP265-273 (p<0.01) and pooled Ś-cell (p<0.01) specificities (Figure 5). The 
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majority of these cells within the PPI15-24 specificity coexpressed CD45RO and CCR7, 
whereas greater variability was apparent for the IGRP265-273 and pooled Ś-cell specificities. 
Expression of CD57 was heterogeneous in all cases. These data confirm the preceding 
observations and define a Ś-cell-specific early memory phenotype associated with type 1 
diabetes.
Ex vivo repertoire analysis of β-cell-specific CD8 T cells
To complement our flow cytometric studies, we examined the TCR repertoire of Ś-cell-
specific CD8 T cell populations using a template-switch anchored RT-PCR to amplify all 
expressed TRB gene rearrangements in an unbiased and quantitative manner (24; 26). The 
PPI15-24 specificity was considered representative for this purpose on the basis of consistent 
phenotypic differences between subject groups across all analyses. Sufficient numbers of 
cognate tetramer-binding CD8 T cells were isolated by ultrapure flow cytometric sorting 
from three type 1 diabetes patients and two healthy controls to enable this analysis. In all 
cases, the ex vivo repertoires were oligoclonal and highly skewed towards one or more 
dominant clonotypes (Table 2). No consistent amino acid patterning or length bias was 
apparent across the third complementarity-determining region (CDR3) and TRB gene usage 
was heterogeneous. Thus, the repertoire of CD8 T cells specific for PPI15-24 is unpredictable 
and private (34).
DISCUSSION
In this study, we combined high definition polychromatic flow cytometry with ultrasensitive 
pHLAI tetramer staining to define the magnitude and differentiation status of Ś-cell-specific 
CD8 T cell populations in type 1 diabetes patients and healthy controls. Moreover, we 
achieved sufficient resolution with this approach to enable direct ex vivo analysis of the 
autoreactive TCR repertoire in a subset of individuals. In contrast to healthy controls, 
patients with newly diagnosed type 1 diabetes displayed hallmarks of antigen-driven 
expansion within the Ś-cell-specific CD8 T cell compartment. No such differences were 
observed between subject groups for persistent viral specificities or CD8 T cells globally. 
Collectively, these data identify phenotypic biomarkers of disease-relevant CD8 T cell-
mediated autoimmunity in type 1 diabetes.
Remarkably, we found that Ś-cell-specific CD8 T cell frequencies in peripheral blood were 
similar between type 1 diabetes patients and healthy controls. These findings are consistent 
with some previous studies of presumed autoimmune conditions (35), but discrepant with 
other reports in the field (6; 17), most likely due to differences in detection sensitivity and 
cohort composition. Of particular note, the use of dasatinib to enhance tetramer staining 
thresholds revealed autoreactive CD8 T cells in the present study that were not visible with 
standard protocols. The reliable identification of naïve precursors in addition to antigen-
experienced subsets readily explains the equivalent frequencies of Ś-cell-specific CD8 T 
cells between subject groups. It is also important to recognize that peripheral CD8 T cell 
frequencies do not necessarily reflect the tissue-localized immune cell environment. Indeed, 
histopathological evaluations of Ś-cell-specific CD8 T cell populations in the insulitic 
lesions of patients who died close to the time of diagnosis have demonstrated pronounced 
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variability in antigen targeting between islets and individuals (3; 36). Accordingly, it is 
difficult to equate quantitative measures of immune autoreactivity in the periphery with CD8 
T cell-mediated events in the pancreas.
In contrast to the lack of simple numerical correlates, we found clear phenotypic signatures 
of functionally relevant Ś-cell-derived antigen exposure in type 1 diabetes patients. 
Conventional subset analyses revealed fewer TN cells and greater numbers of TSCM cells 
across all pooled Ś-cell specificities within the CD8 compartment of patients with newly 
diagnosed type 1 diabetes compared to healthy controls. Single marker evaluations 
confirmed this overall pattern, with reduced expression of CD27 and CCR7 and elevated 
expression of CD57 and CD95. The increased prevalence of antigen-specific TSCM cells, 
which serve as a reservoir to replenish more differentiated memory subsets (16; 37), could 
perpetuate the underlying autoimmune process of Ś-cell destruction. It is also notable that 
granzymes and perforin are strongly coexpressed with CD57, which acts accordingly as a 
surrogate marker of cytolytic activity (38; 39). Such highly differentiated cells may therefore 
associate with more severe disease manifestations (40-42). Multivariate analyses further 
identified a phenotypically distinct CD27intermediateCD95+ population of Ś-cell-specific CD8 
T cells in type 1 diabetes patients that was significantly less frequent in healthy controls, 
again consistent with an antigen-driven disease process as reported previously in a viral 
system (43). Importantly, all three analytical approaches yielded significant differences 
between subject groups solely within the Ś-cell-specific CD8 T cell compartment. Thus, the 
phenotypic profile of tissue-directed autoreactive CD8 T cell populations may act as a useful 
biomarker of disease activity in type 1 diabetes.
In further experiments, we characterized the TCR repertoire of tetramer-binding CD8 T cells 
specific for the PPI15-24 epitope. This specificity was selected on the grounds that robust 
phenotypic differences were detected between type 1 diabetes patients and healthy controls 
across all analytical strategies. Moreover, quantitative differences in the cognate CD8 T cell 
population have previously been reported to associate with disease activity (17). The 
enhanced detection sensitivity afforded by our approach facilitated this analysis, which 
represents the first ex vivo characterization of autoreactive CD8 T cell clonotypes. In all 
cases, we observed highly skewed oligoclonal repertoires reminiscent of virus-driven 
expansions (24). These hierarchical structures could reflect focused autoantigen-specific 
priming or cross-reactivity with an environmental trigger in the form of a highly 
immunogenic pathogen-derived epitope (44). However, it is important to note that this 
clonotypic pattern was not unique to the type 1 diabetes setting. Similar findings in two 
healthy controls, associated with a small central memory expansion in an otherwise largely 
naïve landscape in one (Control 2) and a highly differentiated predominant memory 
phenotype in the other (Control 28), suggest the natural occurrence of heterologous 
responses. Thus, oligoclonal Ś-cell-specific CD8 T cell populations can exist in the memory 
pool of healthy individuals without concomitant evidence of disease activity. It is intriguing 
to speculate that the highly private nature of these repertoires could provide a molecular 
explanation for differential TCR-mediated outcomes in the immunopathogenesis of type 1 
diabetes, akin to recent descriptions in viral systems (45-47).
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Overall, the present study demonstrates that Ś-cell-specific CD8 T cells are more 
differentiated in patients with newly diagnosed type 1 diabetes compared to healthy controls. 
This key result identifies an immune correlate of disease activity that could be further 
refined at the clonotypic level to monitor organ-specific tissue damage in the periphery.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Identification of antigen-specific CD8 T cell populations. A-G: Thawed PBMCs were 
stained with pHLA-A*0201 tetramers representing PPI15-24 (A), InsB10-18 (B), IGRP265-273 
(C), IA-2797-805 (D), GAD65114-123 (E), CMV pp65495-503 (F) and EBV BMLF1280-288 (G). 
Gates were set serially on singlets, live CD3+CD14−CD19− cells and lymphocytes prior to 
Boolean exclusion of dye aggregates and subsequent analysis in bivariate CD8 versus 
tetramer plots (Supplementary Figure 1 A). Representative paired data in the absence or 
presence of dasatinib are shown for type 1 diabetes patients and healthy controls. Tetramer-
binding CD8 T cell frequencies are indicated.
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Figure 2. 
Summary of antigen-specific CD8 T cell frequencies. A-G: Thawed PBMCs were stained 
with pHLA-A*0201 tetramers representing PPI15-24 (A), InsB10-18 (B), IGRP265-273 (C), 
IA-2797-805 (D), GAD65114-123 (E), CMV pp65495-503 (F) and EBV BMLF1280-288 (G). 
Graphs show tetramer-binding CD8 T cell frequencies in the absence (empty symbols) or 
presence (filled symbols) of dasatinib for type 1 diabetes patients (T1D) and healthy controls 
(CTR). No significant differences across identical comparisons were observed between 
subject groups. Bars represent median values. Statistical analyses were performed using the 
Wilcoxon signed-rank test; p values ≤ 0.05 are shown.
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Figure 3. 
Phenotypic subset analysis of antigen-specific CD8 T cells. A: Pie chart representations of 
mean subset percentages for pooled Ś-cell-specific CD8 T cells and individual specificities 
in type 1 diabetes patients (top row) and healthy controls (bottom row). Subsets are defined 
and color-coded as follows: green, TN (CD27+CD45RO−CD57−CD95−CCR7+); yellow, 
TSCM (CD27+CD45RO−CD95+CCR7+); blue, TEFF (CD27−CD45RO−CD95+CCR7−); red, 
all remaining memory cells. B: Column plots showing TN and TSCM subset percentages for 
pooled Ś-cell-specific CD8 T cells and individual specificities in type 1 diabetes patients 
(T1D) and healthy controls (CTR). Representative data are shown in Supplementary Figure 
1 B&C. Almost identical results were obtained with the TN subset defined in the absence of 
CD57 (CD27+CD45RO−CD95−CCR7+). Bars represent median values. Statistical analyses 
were performed using the Mann-Whitney U-test; p values ≤ 0.05 are shown.
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Figure 4. 
Single marker analysis of antigen-specific CD8 T cells. A-E: Percent expression of CD95 
(A), CD57 (B), CD27 (C), CCR7 (D) and CD45RO (E) is shown for type 1 diabetes patients 
(T1D) and healthy controls (CTR) across all CD8 T cells and the indicated specificities. 
Corresponding data for individual Ś-cell-derived epitope-specific CD8 T cell populations are 
shown in Supplementary Figure 4. Bars represent median values. Statistical analyses were 
performed using the Mann-Whitney U-test; p values ≤ 0.05 are shown.
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Figure 5. 
Frequency difference gating analysis of antigen-specific CD8 T cells. Overlays of 
concatenated data from type 1 diabetes patients (cloud plots) and healthy controls (blue dots) 
are shown for the indicated Ś-cell specificities across bivariate phenotypic profiles. 
Populations of CD27intermediateCD95+ CD8 T cells, present at significantly higher 
frequencies in type 1 diabetes patients compared to healthy controls, are displayed as red 
dots.
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Table 1
HLA-A*0201-restricted CD8 T cell epitopes
Antigen Epitope Sequence Subjects*
Preproinsulin PPI15-24 ALWGPDPAAA 14/14
Insulin B chain InsB10-18 HLVEALYLV 10/13
Islet-specific glucose-6-phosphatase
catalytic subunit-related protein
IGRP265-273 VLFGLGFAI 13/12
Islet tyrosine phosphatase IA-2797-805 MVWESGCTV 11/13
Glutamic acid decarboxylase 65 GAD65114-123 VMNILLQYVV 11/10
Cytomegalovirus pp65 CMV pp65495-503 NLVPMVATV 14/13
Epstein-Barr virus BMLF1 EBV BMLF1280-288 GLCTLVAML 13/12
*Numbers of healthy controls/type 1 diabetes patients studied for each epitope specificity.
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Table 2
Clonotypic analysis of CD8 T cells specific for the PPI15-24 epitope
Subject TRBV CDR3 TRBJ Frequency (%)
Control 2 25-1 CASSDLQAGQPQH 1-5 81.48
20-1 CSASVAGEQF 2-1 16.67
25-1 CASSDGQAGQPQH 1-5 1.85
Control 28 10-1 CASSEFRRWNYGYT 1-2 71.74
30 CAWSVNFYINEQF 2-1 28.26
Patient 25 20-1 CSARDLLWTSGEETQY 2-5 75.29
2 CASRPGTGGINEQF 2-1 7.06
9 CASSDYGRGANVLT 2-6 4.71
29-1 CSVQGTGAYEQY 2-7 3.53
4-3 CASSHDADGYT 1-2 3.53
14 CASSPTDRGRGNTEAF 1-1 2.35
9 CASSDFQGAGNTIY 1-3 2.35
10-3 CAISWDRRTYEQY 2-7 1.18
Patient 26 9 CASSGGWREQF 2-1 71.60
10-3 CAISDGDNSHGYT 1-2 16.05
27 CASSLTGTSSYEQY 2-7 8.64
7-7 CASSTYRGRVSLDEQF 2-1 2.47
7-7 CASSTYRGRVSLEEQF 2-1 1.23
Patient 4 27 CASSPTPSTYNEQF 2-1 20.83
5-1 CASSFRTGESYEQY 2-7 16.67
5-6 CASSLGVFGTPSYEQY 2-7 10.42
12-3/12-4 CASSPYGGRNGELF 2-2 10.42
30 CAWALFGSAYEQY 2-7 6.25
29-1 CSVDAPWSSSTDTQY 2-3 4.17
7-2 CASSFYVTGNTEAF 1-1 4.17
30 CAWSVGAGNGYT 1-2 4.17
18 CASSIEVGYEQY 2-7 4.17
7-2 CASSGTGGSYEQY 2-7 4.17
5-1 CASSLAGQGANYGYT 1-2 2.08
12-3/12-4 CASSSRDRVTDTQY 2-3 2.08
18 CASSPSGVRQPQH 1-5 2.08
7-2 CASSLAIGNTEAF 1-1 2.08
5-1 CASSWDRVYNEQF 2-1 2.08
2 CAIPGTALNEQF 2-1 2.08
12-3/12-4 CASSTTDTQY 2-3 2.08
Individual clonotypes are represented in order of relative frequency. Gene usage and CDR3 amino acid sequence are shown in each case.
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